Psychedelics & Cannabis

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.

What should you know about the lesser known psychedelics? Clinical insights from Jacob Perlson, MD, MPH, at the APA Annual Meeting.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

A single dose of psilocybin was associated with a significant and sustained reduction in depressive symptoms and possible improvement of PTSD and burnout experienced by clinicians from the front line of the COVID-19 pandemic.

Dennis S. Charney, MD, discussed the importance of trying and risking failure when studying new potential treatments, as well as the future of treating depression.

Dennis S. Charney, MD, celebrates the 40th anniversary of Psychiatric Times discussing the history of psychiatry and where he hopes the future lies.

Here are highlights from this week in Psychiatric Times, including a special report on psychiatric symptoms of celiac disease and the potential dangers of cannabis use in older patients.

Learn more about the need for closer collaboration between psychiatry and cannabis research to explore its therapeutic potential, mitigate risks, and advance evidence-based mental health treatments.

Why are older patients turning to cannabis for symptom relief?

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Cannabis use disorder and schizophrenia both peak in prevalence around the same age. Is there a cause-and-effect relationship?

Mark Viner, MD, shares his thoughts on the place cannabis holds in psychiatry and addressing the stigma cannabis faces.

As cannabis transitions from an illicit drug to a multi-billion-dollar industry, psychiatry faces both challenges and opportunities in exploring its therapeutic potential while balancing the risks.

Early phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.

Here are highlights from this week in Psychiatric Times, including conference updates and trial news.

With an FDA Breakthrough Therapy Designation, what are the next steps for MM-120?

MindMed has announced the first patient has been dosed in its phase 3 study Panorama.

New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.

Is there a way to separate the neuroplasticity and therapeutic effects from the hallucinatory and dissociative effects of traditional psychedelics?

Understanding the complex relationship between substance use and mental health is critical to providing thorough and well-informed evaluations. Let's take a look at the relationship between cannabis and criminal responsibility.

We asked our contributors at the 63rd meeting of the American College of Neuropsychopharmacology what they are excited about from 2024 and what they are looking forward to in 2025. Here's what they said.

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?